Informations sur le produit
Nom :
Melagatran
Synonymes :
- N-[(1R)-2-[(2S)-2-[[[[4-(Aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]glycineH-319/68
- Glycine, N-[(1R)-2-[(2S)-2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-
- Glycine, N-[2-[2-[[[[4-(aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-, [S-(R*,S*)]-
- H-319/68
- N-[(1R)-2-[(2S)-2-[[[[4-(Aminoiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]glycine
- N-[(1R)-2-{(2S)-2-[(4-carbamimidoylbenzyl)carbamoyl]azetidin-1-yl}-1-cyclohexyl-2-oxoethyl]glycine
Description :
Melagatran is a coumarin derivative that acts as a thrombin receptor antagonist. It has been shown to have anti-thrombotic effects in an experimental model of balloon injury and in a vivo model of arterial thrombosis. Melagatran has been shown to significantly inhibit the progression of atherosclerotic lesions when administered orally, without adverse effects on blood coagulation or liver function. This drug may be useful for the prevention or treatment of cardiovascular disease in patients with hepatic impairment. Melagatran is rapidly converted into melagatran in vivo and has no significant pharmacological activity. The drug can be detected by analytical methods such as high performance liquid chromatography (HPLC).
Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :
Propriétés chimiques
Masse moléculaire :
429.51 g/mol
Formule :
C22H31N5O4
Degré de pureté :
Min. 95%
Couleur/Forme :
White Powder
MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :
